

Practique Clinique et Investigation

Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19

Nisreen H Meiqal¹, Salah M Bensaber¹, Mousa I Jaeda¹, Anton Hermann² and Abdul M Gbaj^{1*}

¹Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tripoli, Libya

²Department of Biosciences, University of Salzburg, Salzburg, Austria

*Correspondence: Abdul M Gbaj, Associate Professor of Genetics and Biochemistry, Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tripoli, Libya, Tel: 9000124567; E-mail: abdulgaj4@hotmail.com

INTRODUCTION

Chloroquine was discovered in 1934 by Hans Andersag (German scientist) while he was working for the Bayer Pharmaceutical Company, and this drug was initially called (Resochin) [1,2]. In 1945, the World Health Organization (WHO) recommended the use of chloroquine in the treatment of malaria, which was a deadly disease in many cases [3,4]. Both chloroquine and hydroxychloroquine (safer analogue) with the chemical formula shown in Figure 1 are currently considered to be important drugs listed as anti-malaria agents according to the WHO, the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA) [5,6]. Moreover, hydroxychloroquine is presently widely used to treat autoimmune diseases such as lupus and rheumatoid arthritis [7,8]. Both medications are considered safe drugs whose side effects are generally mild. However, their use must be subjected to strict rules, and self-treatment (without direct medical supervision) is not recommended due to their narrow therapeutic index [9,10].




Figure 1: Chemical structure of chloroquine and hydroxychloroquine.

ANTI-VIRAL ACTIVITY

In vitro antiviral activity of chloroquine has been identified since the late sixties as scientists were able to inhibit the growth of many different viruses by chloroquine and hydroxychloroquine [11]. More recently, the ability of both drugs to inhibit the growth of viruses from the corona family (2004), as well as later the Ebola virus were identified [12-15]. Subsequently, several in vivo experiments in mice were conducted to test the efficacy in vitro of both drugs to inhibit the growth of viruses. The experiments suggested that the drugs were effective against both corona (OC43) [16,17] and influenza (A H5N1), but lack activity against the Ebola virus [18,19]. In addition, many clinical studies were conducted to test the ability of both chloroquine and hydroxychloroquine to inhibit the growth of viruses [20,21]. These clinical studies indicate that no severe viral infection can be treated with chloroquine or hydroxychloroquine although a modest effect of chloroquine in treating human infection with chronic hepatitis C was reported [22].

Citation: Nisreen H Meiqal, Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19. *Prac Clin Invest* 3(S1): 5-8.

ANTIVIRAL ACTIVITY AGAINST THE EMERGING CORONA VIRUS (SARS-COV2)

After the emergence of the COVID-19 pandemic, many drugs and chemical compounds that inhibited viruses in the past were tested against SARS-CoV2 virus. Initially, *in vitro* investigation of chloroquine's ability to inhibit the emerging corona virus (SARS-CoV2) was reported in China (February 2020) indicating high activity [23,24]. These investigations were followed by several *in vitro* and clinical studies that aimed to demonstrate the ability of chloroquine and hydroxychloroquine to inhibit SARS-CoV2 virus in China and some other countries [25-27].

Based on the results of these studies, the following statements can be concluded:

1. Chloroquine and hydroxychloroquine exhibit good *in vitro* efficacy (anti SARS-CoV2) [25-27].
2. More *in vivo* studies are required to determine the pharmacokinetic properties of Chloroquine and hydroxychloroquine as possible anti SARS-CoV2 drugs.
3. A variety of clinical studies are registered in various countries to test chloroquine and hydroxychloroquine ability to inhibit the emerging corona virus (SARS-CoV2) [28-31]. Accordingly, some specialized institutions in some countries and international consortia started to include chloroquine and hydroxychloroquine as part of their medical protocol to treat COVID19 patients. However, this initiation is regarded problematic due to the lack of proof of efficacy as well as fear of unexpected clinical side effects [32,33].
4. Recently, clinical studies (multinational registry analysis) of the use of chloroquine and hydroxychloroquine with or without a macrolide (a class of natural products that consist of a large macrocyclic lactone ring with one or more deoxy sugars attached) for treatment of COVID-19 was reported based on COVID 19 patients hospitalized in different countries. The achieved results indicated lack of evidence of benefit of both medications to effectively treat COVID 19 patients. In addition, there was an associated increase of ventricular arrhythmias and a greater hazard for in-hospital death with COVID-19 [33-35].
5. Based on the findings listed in point (4), the FDA warned against using of chloroquine and hydroxychloroquine outside the medical framework, the WHO suspended their clinical trials for safety reasons, and their use as part of the treatment protocols were later stopped by the French government.

CONCLUSION

Chloroquine or its analogues appeared a hope for humanity in the treatment of the COVID-19 disease. Chloroquine is cheap and safe (if used under medical supervision), and early results of *in vitro* studies were promising. However, this initial achievement requires further investigation to verify the suitability and safety of their use. Currently, WHO does not recommend any specific antiretroviral drugs against SARS-CoV2, citing the lack of sufficient evidence to recommend any specific treatment that includes chloroquine or its analogues? To determine the efficacy of chloroquine or its analogues to treat COVID 19, it will be necessary to provide more financial support for the continuation of clinical trials.

ACKNOWLEDGEMENT

The authors gratefully acknowledge the technical support and valuable suggestions obtained from Ms. Amira Abdul Gbaj (Novelien Zone, Tripoli, Libya).

REFERENCES

1. SA JM, Chong JL, Wellem TE (2011) Malaria drug resistance: New observations and developments. *Essays in Biochemistry* 51: 137-160.
2. Pou S, Winter RW, Nilsen A, et al. (2012) Sontochin as a Guide to the development of drugs against chloroquine-resistant malaria. *Antimicrobial Agents and Chemotherapy* 56(7): 3475-3480.
3. Beausoleil E (1984) A review of present antimalaria activities in Africa. *Bulletin of the World Health Organization* 62(Suppl): 13-17.
4. Okech BA, Existe A, Romain JR, et al. (2015) Therapeutic efficacy of chloroquine for the treatment of uncomplicated plasmodium falciparum in haiti after many decades of its use. *American Journal of Tropical Medicine & Hygiene* 92(3): 541-545.
5. Mittal L, Zhang L, Feng R, et al. (2018) Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study. *Journal of the American Academy of Dermatology* 78(1): 100-106.
6. Browning DJ (2014) Pharmacology of chloroquine and hydroxychloroquine. *Hydroxychloroquine and Chloroquine Retinopathy* 35-63.
7. Smolen JS, Landewe R, Breedveld FC, et al. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Annals of the Rheumatic Diseases* 73(3): 492-509.
8. Urman A, Taklalsingh N, Sorrento C, et al. (2018) Inflammation beyond the joints: Rheumatoid arthritis and cardiovascular disease. *Scifed Journal of Cardiology* 2(3): 1000019.
9. Savage DE, Plotnik R, Wozniak RA (2020) Short-term, high-dose hydroxychloroquine corneal toxicity. *American Journal of Ophthalmology Case Reports* 18: 100713.
10. Motarjemzadeh Q, Aidenloo NS, Abbaszadeh M (2016) Detection of hydroxychloroquine retinal toxicity by automated perimetry in 60 rheumatoid arthritis patients with normal fundoscopic findings. *Global Journal of Health Science* 8: 59-64.
11. Dyall J, Gross R, Kindrachuk J, et al. (2017) Middle east respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. *Drugs* 77(18): 1935-1966.
12. Zimmermann P, Curtis N (2020) Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. *The Pediatric Infectious Disease Journal* 39(5): 355-368.
13. Chan JFW, Lau SKP, To KKW, et al. (2015) Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing sars-like disease. *Clinical Microbiology Reviews* 28: 465-522.
14. Dhama K, Karthik K, Khandia R, et al. (2018) Advances in designing and developing vaccines, drugs, and therapies to counter ebola virus. *Frontiers in Immunology* 9: 1803.
15. Xiao JH, Rijal P, Schimanski L, et al. (2018) Characterization of influenza virus pseudotyped with *Ebola virus* glycoprotein. *Journal of Virology* 92: e00941-e01017.
16. Wang S, Zhang L, Zhang R, et al. (2018) Identification of two residues within the NS1 of H7N9 influenza A virus that critically affect the protein stability and function. *Veterinary Research* 49: 98.
17. Liu G, Park HS, Pyo HM, et al. (2015) Influenza A virus panhandle structure is directly involved in RIGI-I activation and interferon induction. *Journal of Virology* 89: 6067-6079.
18. Dhama K, Karthik K, Khandia R, et al. (2018) Advances in designing and developing vaccines, drugs, and therapies to counter *Ebola virus*. *Frontiers in Immunology* 9: 1803.

19. Dowall SD, Bosworth A, Watson R, et al. (2015) Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. *Journal of Genetics Virology* 96(12): 3484-3492.
20. Savarino A, Boelaert JR, Cassone A, et al. (2003) Effects of chloroquine on viral infections: An old drug against today's diseases. *The Lancet Infectious Disease* 3(11): 722-727.
21. Delvecchio R, Higa LM, Pezzuto P, et al. (2016) Chloroquine, an Endocytosis blocking agent, inhibits *Zika virus* infection in different cell models. *Viruses* 8(12): 322.
22. Rodrigo C, Fernando SD, Rajapakse S (2020) Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: A systematic review. *Clinical Microbiology and Infection*.
23. Wang M, Cao R, Zhang L, et al. (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) *in vitro*. *Cell Res* 30: 269-271.
24. Yavuz SS, Unal S (2020) Antiviral treatment of COVID-19. *Turkish Journal of Medical Sciences* 50: 611-619.
25. Felsenstein S, Herbert JA, McNamara PS, et al. (2020) COVID-19: Immunology and treatment options. *Clinical Immunology* 215: 108448.
26. Roustit M, Guilhaumou R, Molimard M, et al. (2020) Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. *Therapies*.
27. Quiros RE, Biasiotto G, Magro P, et al. (2020) The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? *Pharmacological Research* 158: 104904.
28. Huang J, Song W, Huang H, et al. (2020) Pharmacological therapeutics targeting RNA-Dependent RNA Polymerase, proteinase and spike protein: From mechanistic studies to clinical trials for COVID-19. *Journal of Clinical Medicine* 9(4): 1131.
29. Abd El-Aziz TM, Stockand JD (2020) Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. *Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases*. 83: 104327.
30. Tobaiqy M, Qashqary M, Al Dahery S, et al. (2020) Therapeutic management of patients with COVID-19: A systematic review. *Infection Prevention in Practice* 2(3): 100061
31. Zhang J, Xie B, Hashimoto K (2020) Current status of potential therapeutic candidates for the COVID-19 crisis. *Brain Behaviour & Immunology* 87: 59-73.
32. Yan Y, Shin WI, Pang YX, et al. (2020) The first 75 days of novel coronavirus (SARS-CoV-2) outbreak: Recent advances, prevention, and treatment. *International Journal of Environmental Research & Public Health* 17(7): 2323.
33. Mehra MR, Desai SS, Ruschitzka F, et al. (2020) Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *The Lancet*.
34. Roustit M, Guilhaumou R, Molimard M, et al. (2020) Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. *Therapie* S0040-5957(20): 30100-30101.
35. CarriÃ¨re F, Longhi S, Record M (2020) The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway. *Biochimie* 175.